As it focuses on longer-term growth opportunities, cancer screening test maker Exact Sciences Corp. is pausing on previous plans to build a new research and development facility in Madison, according to the company.
The company still intends to fulfill its commitment to create 1,300 Wisconsin jobs and invest $350 million in its facilities by 2025, Exact Sciences director of corporate communications Stephanie Spanos said via email on Feb. 3.
Exact Sciences (Nasdaq: EXAS), which is known for its at-home colorectal cancer screening test Cologuard, has been focused on reaching profitability. It laid off at least 580 employees in 2022, citing economic factors and the reprioritization of programs.
